Vetoquinol receives FDA approval for its antiparasitic Felpreva in the United States
The veterinary laboratory announced on November 16, 2026 that the Food & Drug Administration had authorized the marketing of Felpreva in the United States, an antiparasitic for cats already sold in Europe.
Its chairman and chief executive officer said he was pleased to be able to offer it to American veterinarians and cat owners.
A broad-spectrum topical treatment applied four times a year
Felpreva is a broad-spectrum antiparasitic intended for cats. It is administered as a topical treatment, with only four applications per year. In the United States as in Europe, it is dispensed only on prescription and reserved exclusively for cats.
Matthieu Frechin, chairman and chief executive officer of Vetoquinol, summarized the product's core argument as follows: “Felpreva simplifies parasite control for both veterinarians and cat owners by offering a simple solution: fewer applications for treatment and broad-spectrum protection.”
After a European launch in 2022, the opening of the American market
Launched in Europe in 2022, Felpreva has, according to the company, “gained the trust of European veterinarians and cat owners.” The FDA authorization now paves the way for its commercialization in the United States.
Founded in 1933 and listed on Euronext Paris since 2006, Vetoquinol specializes exclusively in animal health and operates in Europe, the Americas and Asia-Pacific. The group will publish its 2026 annual revenue on January 14, 2027, after the market closes.